Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.

EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer

EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer

EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer

EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients

EP: 7.Highlighting the Available CDK4/6 Inhibitors

EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC

EP: 9.Applying NCCN Guidelines in the Treatment of mBC

EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

Now Viewing

EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs

EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer

EP: 14.Academic and Community Practice Collaboration in mBC Treatment

EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment

EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment

EP: 17.Alternative Treatments for eBC and mBC

EP: 18.Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective

EP: 19.Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care

EP: 20.Key Takeaways on mBC and eBC

Related Videos

Related Content

Advertisement

June 4th 2025

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Gillian McGovern, Associate Editor

May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor

June 2nd 2025

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

Alexandra Gerlach, Associate Editor

April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor

May 23rd 2025

APOBEC3 Mutagenesis May Drive Therapy Resistance in Patients With Breast Cancer

Alexandra Gerlach, Associate Editor

May 21st 2025

Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast Cancer

Grace Morrison, PharmD Candidate

Related Content

Advertisement

June 4th 2025

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Gillian McGovern, Associate Editor

May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor

June 2nd 2025

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

Alexandra Gerlach, Associate Editor

April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor

May 23rd 2025

APOBEC3 Mutagenesis May Drive Therapy Resistance in Patients With Breast Cancer

Alexandra Gerlach, Associate Editor

May 21st 2025

Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast Cancer

Grace Morrison, PharmD Candidate